Trial register facet
Phase 2 trial records
92 records at phase 2.
Showing 0 records on this page
Records
92 documents · page 1 of 4
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| SURVO-PH2-OBESITY | Survodutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 387 | 2024 | Moderate |
| SURVO-PH2-MASH | Survodutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 295 | 2024 | Low |
| SYNERGY-NASH | Tirzepatide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 190 | 2024 | Low |
| MARITIDE-PH2-OBESITY | Maridebart cafraglutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 592 | 2024 | Low |
| MARITIDE-PH2-T2D | Maridebart cafraglutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Low |
| SURVO-PH2-OBESITY-ELDERLYprogramme record | Survodutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| MARITIDE-PH2-T2D-BODY-COMPprogramme record | Maridebart cafraglutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SURVO-PH2-OBESITY-OLEprogramme record | Survodutide | Phase 2 | Reported | Single-arm open-label | — | 2024 | Very low |
| SYNERGY-NASH-QOLprogramme record | Tirzepatide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SURVO-PH2-OBESITY-ADHERENCEprogramme record | Survodutide | Phase 2 | Reported | Observational | — | 2024 | Very low |
| SYNERGY-NASH-BODY-COMPprogramme record | Tirzepatide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| RETA-PH2-OBESITY | Retatrutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 338 | 2023 | Moderate |
| RETA-PH2-T2D | Retatrutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 281 | 2023 | Moderate |
| ORFO-PH2-OBESITY | Orforglipron | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 272 | 2023 | Moderate |
| ORFO-PH2-T2D | Orforglipron | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 383 | 2023 | Moderate |
| CAGRI-SEMA-PH2-T2D | CagriSema (cagrilintide with semaglutide) | Phase 2 | Reported | Randomised, double-blind, active-controlled | 92 | 2023 | Low |
| MAZ-PH2-OBESITY | Mazdutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 248 | 2023 | Moderate |
| CAGRI-SEMA-PH2-T2D-QOLprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| MAZ-PH2-OBESITY-BODY-COMPprogramme record | Mazdutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| ORFO-PH2-OBESITY-QOLprogramme record | Orforglipron | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| MAZ-PH2-OBESITY-QOLprogramme record | Mazdutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| CAGRI-SEMA-PH2-T2D-BODY-COMPprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| CAGRI-PH2-DOSEFIND | Cagrilintide | Phase 2 | Reported | Dose-finding | 706 | 2021 | Moderate |
| TESA-NAFLD-PH2 | Tesamorelin | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 61 | 2019 | Low |
page 1 of 4